{"slug":"retatrutide-glp-1","verification":{"valid":true,"entries":5,"head":"fb667321f14177f9e0c881e290121287bdeead31e16e913221a502663e29bdf6"},"count":5,"sources":[{"id":"s1","type":"pubmed","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2301972","title":"Triple–Hormone-Receptor Agonist Retatrutide for Obesity","quote":"treatment with the 12-mg dose of retatrutide... resulted in a mean weight reduction of 24.2% after 48 weeks.","summary":"Phase 2 human trial results establishing 24.2% weight loss.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:00:17.103Z","link_status":"http_403","quote_status":"unverified","prev":"genesis","hash":"2db06e67185a5a01bb5ad02bcd04939018bc57e5309017431b2029cb698818ce"},{"id":"s2","type":"news","url":"https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss","title":"Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial","quote":"participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving ≥30% weight loss","summary":"TRIUMPH-1 phase 3 topline data.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:00:17.103Z","link_status":"ok","quote_status":"unverified","prev":"2db06e67185a5a01bb5ad02bcd04939018bc57e5309017431b2029cb698818ce","hash":"2a1a7c06c39be6465dc13220e80fd9ff34d3e364dab570b00fc8eb5f87f5d0ca"},{"id":"s3","type":"news","url":"https://www.clinicaltrialsarena.com/news/lilly-retatrutide-data-phase-iii-trial/","title":"Lilly's triple G agonist boasts 28.7% weight loss in Phase III trial","quote":"Participants on the 12 mg dose lost an average of 28.7% of body weight... WOMAC pain scores were reduced by up to 4.5 points — a 75.8% reduction","summary":"TRIUMPH-4 osteoarthritis cohort results.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:00:17.103Z","link_status":"ok","quote_status":"unverified","prev":"2a1a7c06c39be6465dc13220e80fd9ff34d3e364dab570b00fc8eb5f87f5d0ca","hash":"54fcfd3dfe6ee0e4e759158540f3743d0e83b5e621547320121806fa74aecc59"},{"id":"s4","type":"review","url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01053-X/abstract","title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist...","quote":"Retatrutide... agonist activity at the GIP, GLP-1, and glucagon receptors","summary":"Mechanism and phase 2 diabetes trial summary.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:00:17.103Z","link_status":"http_403","quote_status":"unverified","prev":"54fcfd3dfe6ee0e4e759158540f3743d0e83b5e621547320121806fa74aecc59","hash":"9210ca564806579ff316123edddb776c581721a699744da3ba5de1b7d1742cec"},{"id":"s5","type":"news","url":"https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss","title":"Lilly phase 3 safety summary","quote":"discontinuation was 18% at 12mg (vs 4% placebo)","summary":"Adverse event and discontinuation rates from phase 3.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T01:00:17.103Z","link_status":"ok","quote_status":"unverified","prev":"9210ca564806579ff316123edddb776c581721a699744da3ba5de1b7d1742cec","hash":"fb667321f14177f9e0c881e290121287bdeead31e16e913221a502663e29bdf6"}]}